NC-410
- Generic Name
- NC-410
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Phase 2
Not yet recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Target Recruit Count
- 20
- Registration Number
- NCT06941857
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Ovarian CancerColo-rectal CancerAdvanced or Metastatic Solid TumorsLung CancerMicrosatellite Instability HighMicrosatellite StableEndometrial CancerCervical CancerEsophageal CancerMicrosatellite Instability Low
- Interventions
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- NextCure, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT05572684
- Locations
- 🇺🇸
Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸Rocky Mountain Cancer Centers, Aurora, Colorado, United States
🇺🇸St. Elizabeth Edgewood Hospital, Edgewood, Kentucky, United States
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1
Terminated
- Conditions
- Ovarian CancerGastric CancerColo-rectal CancerAdvanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- NextCure, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT04408599
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸NIH National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath